Lord, Abbett & Co. LLC Apellis Pharmaceuticals, Inc. Transaction History

Lord, Abbett & Co. LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Oct 07, 2024	SELL	$55.39 - $72.47 $56.2 Million - $73.5 Million	-1,014,143 Reduced 94.94%	54,000 $3.17 Million
Q1 2024 May 09, 2024	BUY	$55.39 - $72.47 $2.99 Million - $3.91 Million	54,000 New	54,000 $3.17 Million
Q2 2023 Oct 07, 2024	BUY	$76.68 - $93.31 $12.6 Million - $15.3 Million	163,915 Added 18.13%	1,068,143 $97.3 Million
Q2 2023 Aug 14, 2023	BUY	$76.68 - $93.31 $12.6 Million - $15.3 Million	163,915 Added 18.13%	1,068,143 $97.3 Million
Q1 2023 Oct 07, 2024	SELL	$46.59 - $66.96 $10.6 Million - $15.3 Million	-228,395 Reduced 20.17%	904,228 $59.6 Million
Q1 2023 May 12, 2023	SELL	$46.59 - $66.96 $10.6 Million - $15.3 Million	-228,395 Reduced 20.17%	904,228 $59.6 Million
Q4 2022 Oct 07, 2024	BUY	$43.24 - $61.04 $49 Million - $69.1 Million	1,132,623 New	1,132,623 $58.6 Million
Q4 2022 Feb 10, 2023	BUY	$43.24 - $61.04 $8.05 Million - $11.4 Million	186,097 Added 19.66%	1,132,623 $58.6 Million
Q3 2022 Nov 14, 2022	BUY	$44.76 - $69.66 $42.4 Million - $65.9 Million	946,526 New	946,526 $64.6 Million

308

115M

3.85M

1.09M

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.64B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of Lord, Abbett & Co. LLC, based on Form 13F filings with the SEC.

Stay updated on Lord, Abbett & Co. LLC with notifications on news.